Underweight: Trim to 75% — Unfavorable R/R at $89.41, Await Confirmation Above $89.69 on 8M+ Volume
Underweight (trim to ~75% of model weight), replace proposed collar with $92-95 strike covered call post-FY27 Q1 earnings expiry, maintain $88.58 hard stop (close below 200 SMA on volume >7M = exit remaining longs), and define symmetric re-entry triggers above $89.69 (>8M volume, 2 sessions) or below $82 (positive MACD divergence). The aggressive analyst is correct that fundamentals are improving; the conservative analyst is correct that R/R at current levels is unfavorable; the neutral analyst is correct that execution should not triple-stack risk overlays. This decision captures the constructive drift without overpaying for it.
| Position | Action |
|---|---|
| Current position exceeds 75% of model weight | Trim to 75% of model weight |
| Position at or below 75% model weight | Hold; do not add until entry triggers fire |
| Position capped at neutral weight even on confirmed breakout | Cap at neutral model weight — 13.9x forward multiple has already priced in recovery thesis |
Medtronic is undergoing a structural regime change — not a momentum rally — as technicals confirm a breakout above the 200 SMA, UBS flips to Buy on a turnaround thesis, revenue accelerates to record highs, and EPS normalizes from depressed $3.73 TTM toward $6.41 consensus, all while the stock trades at a discounted 13.9x forward P/E that prices in zero optionality.
| Indicator | Value | Signal |
|---|---|---|
| close | 89.41 | neutral |
| open | 87.16 | neutral |
| high | 89.45 | neutral |
| low | 86.71 | neutral |
| volume | 6570031 | neutral |
| 10 EMA | 86.44 | bullish |
| 50 SMA | 81.69 | bullish |
| 200 SMA | 88.58 | bullish |
| VWMA | 85.84 | bullish |
| MACD | 1.69 | bullish |
| MACD signal | 1.44 | bullish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Pullback to $80-82 with positive MACD divergence
Then: Re-engage with improved risk/reward on bull trap invalidation
UBS upgraded MDT from Neutral to Buy as a 'turnaround story,' representing a Tier-1 sell-side inflection, and Medtronic received a CE Mark expansion for the Affera Mapping & Ablation System with Sphere-9 catheter for ventricular arrhythmia.
↩ rebuts: “Bear claims this is just a story stock pumping on retail chatter”
EV: +40% (Motley Fool target implies $125+) · concedes: A 3.4% extension from the 10 EMA is meaningful and a pullback to $86 on rising volume would be a gift, not a warning sign; Hugo cannot catch Da Vinci in robotics — it is a single product line in a four-segment portfolio; Top line growth is only 3-4%; Net debt is elevated at $26B (though declining); Tariffs, FX, and reimbursement overhang are real but already in the price at 14x forward P/E; Absence of retail froth is constructive but means this is a fundamentals-driven institutional move; Stock has already rallied ~22% from May lows near $73 to $89.41
MDT at $89.41 is a bull trap at upper Bollinger band resistance with an already-priced-in EPS recovery, a structurally over-levered balance sheet ($26B net debt, negative tangible book), and a competitive set that is structurally out-executing Medtronic — the asymmetric setup is decisively to the downside toward $80-$82.
EV: -$9.41 to -$11.06 (price target $80-$82 from $89.41 entry) · concedes: Affera CE Mark expansion is a real regulatory event; FCF of $5.4B does cover dividend and buybacks; Dividend yield of 3.3% provides income support; 28-year dividend increase streak exists (though framed as a liability); RSI not yet in overbought territory (67.69 vs 70 threshold); MACD is technically positive
→ vs aggressive: Traders who plan collar hedges at 89.41 'cap gains, pay for protection against a 22% bear case' they don't need, and miss the upside of early commitment to the re-rating thesis
→ vs conservative: Bollinger band rejection call is 'mismeasured' - close at 89.41 within 24 cents of 89.69 band on a weak market day shows relative strength, not distribution; selling the 200 SMA breakout on the day it prints is 'fighting the tape'
→ vs neutral: 'HOLD and add on weakness below $88' is contradictory - waiting for pullback to 88.58 means waiting for support to fail; if it holds, trader misses entry; if it fails, the 'add on weakness' thesis evaporates
| MACD histogram | 0.25 | bullish |
| RSI | 67.69 | bullish |
| BOLL mid | 84.52 | bullish |
| BOLL upper | 89.69 | neutral |
| BOLL lower | 79.35 | bearish |
| ATR | 2.23 | neutral |
Support: 88.58 · 86.44 · 85.84 · 84.52 · 81.69 · 79.35 | Resistance: 89.69 · 89.45
MDT has transitioned from a sustained downtrend (Nov 2025 highs near $103 to May 2026 lows near $73) into a confirmed medium-term uptrend, with close at 89.41 marking a decisive cross above the 200 SMA at 88.58. Full bull-stack alignment: price above 10 EMA (86.44), 50 SMA (81.69), 200 SMA (88.58), and VWMA (85.84). MACD positive and expanding (line 1.69, signal 1.44, histogram +0.25); RSI strong at 67.69 but not overbought; price testing upper Bollinger band at 89.69. Trigger for trend-following entries: sustained daily close above 89.69. Hard invalidation: daily close below 88.58.
Market Cap
$114.4 B
Current Price
~$89.34
P/E (TTM)
23.97x
Forward P/E
13.94x
PEG Ratio
1.72
P/B
2.31x
EV/EBITDA (TTM)
~13.7x
Dividend Yield
3.30%
Beta
0.566
TTM Revenue
~$36.4 B
TTM Gross Profit
~$23.7 B
TTM Gross Margin
65.3%
TTM Operating Margin
22.0%
TTM Net Margin
13.2%
TTM EPS
$3.73
Forward EPS
$6.41
Q1 FY26 Revenue
$9,807M
Q4 FY25 Revenue
$9,017M
Q3 FY25 Revenue
$8,961M
Q2 FY25 Revenue
$8,578M
Q1 FY25 Revenue
$8,927M
Q1 FY26 Gross Margin
65.3%
Q1 FY26 Operating Margin
20.5%
Q1 FY26 Diluted EPS
$0.96
Q4 FY25 Diluted EPS
$0.89
Q3 FY25 Diluted EPS
$1.07
Q2 FY25 Diluted EPS
$0.81
Q1 FY25 Diluted EPS
$0.82
Total Assets
$93,028M
Cash & ST Investments
$9,220M
Goodwill & Intangibles
$52,733M
Tangible Book Value
($3,270M)
Total Debt
$27,961M
Net Debt
$25,952M
Stockholders' Equity
$49,463M
Current Ratio
2.13x
Debt-to-Equity
58.2%
Working Capital
$13.1B
TTM Operating Cash Flow
~$7,330M
TTM Capital Expenditures
($1,904M)
TTM Free Cash Flow
~$5,425M
TTM Cash Dividends Paid
($3,639M)
Net Share Repurchases
($1,035M)
Acquisitions
($406M)
CapEx % of Revenue
5.2%
FCF Yield
~4.0%
ROE
9.8%
ROA
4.9%
52-Week Range
$73.31–$106.33
50-DMA
$81.68
200-DMA
$89.88
vs. 200-DMA
-0.6%
Interest Expense
$176–181M
Strengths
Concerns
Medtronic demonstrates a compelling earnings recovery narrative with TTM P/E of 23.97x compressing dramatically to Forward P/E of 13.94x on expected EPS recovery from $3.73 to $6.41. The recent Q1 FY26 quarter showed accelerating top-line momentum with record $9.81B revenue, best-in-class 65.3% gross margins, and improving operating margins, though the stock trades slightly below its 200-day moving average of $89.88. With ~$5.4B TTM free cash flow supporting a 3.30% dividend yield (28-year growth streak), a defensive 0.57 beta profile, and meaningful deleveraging reducing net debt by ~$2B, the fundamental setup is constructive for long-term investors; however, $27.9B in total debt, $52.7B in goodwill/intangibles, and execution risk on the EPS recovery path present structural headwinds that warrant a cautious HOLD stance with accumulation preferred on weakness.
Macro: Fed priced to hold rates flat through 2026 (86% no-cut odds); oil bid reviving inflation fears; US recession probability 8% (low). Higher-for-longer rate regime favors low-duration, cash-flow-rich names like MDT. Geopolitical tail-risk premium rising (Hormuz uncertainty) supports defensive sectors like medical devices.